EyePoint Q2 Loss Widens to $94.5M; LUGANO Wet AMD Data Due This Month, Cash Runway into Q4 2027

summarizeSummary

EyePoint's Q2 loss ballooned to $94.5M as it advances DURAVYU toward pivotal data. LUGANO wet AMD results are expected this month, with $180M in cash providing runway into Q4 2027.

check_boxKey Events · Earnings and Guidance · EYPT

• Q2 Net Loss Widens to $94.5M

  Net loss reached $94.5 million ($1.09/share) vs. $59.4 million a year ago, driven by a 48% jump in R&D expenses to $83.6 million for DURAVYU Phase 3 trials and manufacturing scale-up.

• LUGANO Wet AMD Data Imminent

  Topline results from the pivotal Phase 3 LUGANO trial in wet AMD are expected in August 2026, with the LUCIA trial to follow in Q4 2026. Over 900 patients are enrolled across both studies.

• Cash Runway into Q4 2027

  Cash and investments totaled $180 million as of June 30, 2026, down from $223 million at March 31, 2026. Management expects this to fund operations into Q4 2027, beyond the LUGANO and LUCIA readouts.

• DME Trials Fully Enrolled

  The COMO and CAPRI Phase 3 DME trials completed enrollment of over 480 patients in five months, with topline data anticipated in Q4 2027.

auto_awesomeAnalysis · EYPT · Industrial Applications And Services

EyePoint reported a steep Q2 net loss of $94.5 million, up from $59.4 million a year ago, as R&D spending surged for its DURAVYU Phase 3 programs. The company holds $180 million in cash, funding operations into Q4 2027 — past the expected LUGANO topline data this month and LUCIA data in Q4 2026. With LUGANO results imminent, the readout is a binary event that could validate DURAVYU's potential in the $15B+ wet AMD market or raise doubts about the program. The full enrollment of the DME trials and the appointment of a Chief Strategic Science Officer add to the narrative of a company at a critical inflection point.